Diagnosis and management of Sjögren syndrome

American Family Physician

Volumn 79, Issue 6, 2009, Pages

  Kruszka, Paul ^a,c   O'Brian, Robert J ^b  

^a U S COAST GUARD   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINUCLEAR ANTIBODY; ARTIFICIAL TEAR; CEVIMELINE; CYCLOSPORIN; CYCLOSPORIN A; FLUORIDE; HYDROXYCHLOROQUINE; INFLIXIMAB; MOUTHWASH; PILOCARPINE; PLACEBO; RHEUMATOID FACTOR; RITUXIMAB; STEROID; XYLITOL;

ARTHRALGIA; AUTOIMMUNE THYROIDITIS; CLINICAL TRIAL; DENTAL CARIES; DIFFERENTIAL DIAGNOSIS; DRY EYE; FATIGUE; FEVER; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HISTOLOGY; HUMAN; KIDNEY DISEASE; LABORATORY TEST; LIP BIOPSY; LUNG DISEASE; LYMPHADENOPATHY; MORTALITY; MOUTH HYGIENE; PATHOGENESIS; PERIPHERAL NEUROPATHY; PHYSICAL EXAMINATION; PROGNOSIS; RAYNAUD PHENOMENON; REVIEW; SALIVARY GLAND BIOPSY; SJOEGREN SYNDROME; VASCULITIS; XEROPHTHALMIA; XEROSTOMIA; ARTICLE; FEMALE; MALE; MIDDLE AGED;

FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; SJOGREN'S SYNDROME; XEROPHTHALMIA; XEROSTOMIA;

EID: 64849099188     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Fox RI. Sjögren's syndrome. Lancet. 2005;366 (9482):321-331. (Pubitemid 41019424)
2. Sánchez-Guerrero J, Pérez-Dosal MR, Cárdenas- Velázquez F, et al. Prevalence of Sjögren's syndrome in ambulatory patients according to the American- European Consensus Group criteria. Rheumatology (Oxford). 2005;44(2):235-240. (Pubitemid 40277410)
3. Pillemer SR, Matteson EL, Jacobsson LT, et al. Incidence of physician-diagnosed primary Sjögren syndrome in residents of Olmsted County, Minnesota. Mayo Clin Proc. 2001;76(6):593-599. (Pubitemid 32525134)
4. García-Carrasco M, Ramos-Casals M, Rosas J, et al. Primary Sjögren syndrome: clinical and immunologic disease patterns in a cohort of 400 patients. Medicine (Baltimore). 2002;81(4):270-280. (Pubitemid 34755936)
5. Hansen A, Lipsky PE, Dörner T. Immunopathogenesis of primary Sjögren's syndrome: implications for disease management and therapy. Curr Opin Rheumatol. 2005;17(5):558-565. (Pubitemid 41527815)
6. Tzioufas AG, Wassmuth R, Dafni UG, et al. Clinical, immunological, and immunogenetic aspects of autoantibody production against Ro/SSA, La/SSB and their linear epitopes in primary Sjögren's syndrome (pSS): a European multicentre study. Ann Rheum Dis. 2002;61(5):398-404. (Pubitemid 34496817)
7. Cummins MJ, Papas A, Kammer GM, Fox PC. Treatment of primary Sjögren's syndrome with low-dose human interferon alfa administered by the oromucosal route: combined phase III results. Arthritis Rheum. 2003;49(4):585-593. (Pubitemid 36988314)
8. Mariette X, Ravaud P, Steinfeld S, et al. Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS). Arthritis Rheum. 2004;50(4):1270-1276. (Pubitemid 38488821)
9. Vivino FB, Katz WA. Sjogren's syndrome: clinical picture and diagnostic tests. J Musc Med. 1995;12(3):40-52.
10. al-Hashimi I. The management of Sjögren's syndrome in dental practice. J Am Dent Assoc. 2001; 132(10):1409-1417. (Pubitemid 33613229)
11. Ovchinsky A, Har-El G. Salivary gland enlargement. In: Lucent FE, ed. Essentials of Otolaryngology. 5th ed. Philadelphia, Pa.: Lippincott Williams & Wilkins;2003:223-226.
12. Al-Hashimi I, Khuder S, Haghighat N, Zipp M. Frequency and predictive value of the clinical manifestations in Sjögren's syndrome. J Oral Pathol Med. 2001;30(1):1-6. (Pubitemid 32044873)
13. Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjögren's syndrome. Arch Intern Med. 2004;164(12):1275-1284. (Pubitemid 38828877)
14. Pertovaara M, Korpela M, Uusitalo H, et al. Clinical follow up study of 87 patients with sicca symptoms (dryness of eyes or mouth, or both). Ann Rheum Dis. 1999;58(7):423-427. (Pubitemid 29317953)
15. Vitali C, Bombadieri S, Jonsson S, et al., for the European Study Group on Classification Criteria for Sjögren's Syndrome. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61(6):554-558.
16. Fox RI, Stern M, Michelson P. Update in Sjögren syndrome. Curr Opin Rheumatol. 2000;12(5):391-398. (Pubitemid 30676856)
17. Carter SR. Eyelid disorders: diagnosis and management. Am Fam Physician. 1998;57(11):2695-2702. (Pubitemid 28280501)
18. Sreebny LM, Yu A, Green A, Valdini A. Xerostomia in diabetes mellitus. Diabetes Care. 1992;15(7):900-904.
19. Kim J. The use of vital dyes in corneal disease. Curr Opin Ophthalmol. 2000;11(4):241-247. (Pubitemid 30490801)
20. Whitcher JP. The treatment of dry eyes. Br J Ophthalmol. 2004;88(5):603-604. (Pubitemid 38526638)
21. Tsifetaki N, Kitsos G, Paschides CA, et al. Oral pilocarpine for the treatment of ocular symptoms in patients with Sjögren's syndrome: a randomised 12 week controlled study. Ann Rheum Dis. 2003;62(12):1204-1207. (Pubitemid 37500628)
22. Ono M, Takamura E, Shinozaki K, et al. Therapeutic effect of cevimeline on dry eye in patients with Sjögren's syndrome: a randomized, double-blind clinical study. Am J Ophthalmol. 2004;138(1):6-17. (Pubitemid 38850244)
23. Ship JA. Diagnosing, managing, and preventing salivary gland disorders. Oral Dis. 2002;8(2):77-89. (Pubitemid 34298346)
24. Burt BA. The use of sorbitol- and xylitol-sweetened chewing gum in caries control [published correction appears in J Am Dent Assoc. 2006;137(4):447]. J Am Dent Assoc. 2006;137(2):190-196.
25. Wu CH, Hsieh SC, Lee KL, Li KJ, Lu MC, Yu CL. Pilocarpine hydrochloride for the treatment of xerostomia in patients with Sjögren's syndrome in Taiwan - a doubleblind, placebo-controlled trial. J Formos Med Assoc. 2006;105(10):796-803. (Pubitemid 44717618)
26. Fife RS, Chase WF, Dore RK, et al. Cevimeline for the treatment of xerostomia in patient's with Sjögren syndrome: a randomized trial. Arch Intern Med. 2002; 162(11):1293-1300. (Pubitemid 34595036)
27. Shiozawa S, Tanaka Y, Shiozawa K. Single-blinded controlled trial of low-dose oral IFN-alpha for the treatment of xerostomia in patients with Sjögren's syndrome. J Interferon Cytokine Res. 1998;18(4):255-262. (Pubitemid 28176009)
28. Ramos-Casals M, Tzioufas AG, Font J. Primary Sjögren's syndrome: new clinical and therapeutic concepts. Ann Rheum Dis. 2005;64(3):347-354. (Pubitemid 40283042)
29. Theander E, Manthorpe R, Jacobsson LT. Mortality and causes of death in primary Sjögren's syndrome: a prospective cohort study. Arthritis Rheum. 2004;50(4):1262-1269. (Pubitemid 38480838)
30. Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med. 2005; 165(20):2337-2344. (Pubitemid 41640845)
31. Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren's syndrome. Arthritis Rheum. 2002;46(3):741-747. (Pubitemid 34214255)
32. Ramos-Casals M, Brito-Zerón P, Yagüe J, et al. Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjögren's syndrome. Rheumatology (Oxford). 2005;44(1):89-94. (Pubitemid 40124338)
33. Skopouli FN, Dafni U, Ioannidis JP, Moutsopouls HM. Clinical evolution, and morbidity and mortality of primary Sjögren's syndrome. Semin Arthritis Rheum. 2000;29(5):296-304. (Pubitemid 30235981)
34. Brito-Zerón P, Ramos-Casals M, Bove A, Sentis J, Font J. Predicting adverse outcomes in primary Sjögren's syndrome: identification of prognostic factors. Rheumatology (Oxford). 2007;46(8):1359-1362. (Pubitemid 47244514)